R&D News | pharmaphorum

News

Pinky promise made by stone statue hands

Alnylam bets on Tenaya RNAi tech, and other licensing news

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

PepGen slumps as FDA places hold on lead drug

Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

News

Five projects share £100m UK-US Cancer Grand Challenges fund

Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.

News

Moderna agrees $950m settlement of mRNA jab litigation

Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.

Alnylam bets on Tenaya RNAi tech, and other licensing news

PepGen slumps as FDA places hold on lead drug

Can GLP-1 drugs help tackle addiction?

Welsh firm Antiverse raises funds for AI antibody platform

Five projects share £100m UK-US Cancer Grand Challenges fund

Moderna agrees $950m settlement of mRNA jab litigation

Roche launches liver disease algorithm panel

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks